FY2025 Earnings Forecast for ELAN Issued By Leerink Partnrs

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Research analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of Elanco Animal Health in a research note issued to investors on Thursday, July 17th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $0.85 per share for the year, up from their prior forecast of $0.84. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's Q4 2025 earnings at $0.15 EPS and FY2026 earnings at $0.95 EPS.

Several other equities analysts have also recently weighed in on ELAN. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research report on Thursday. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Stifel Nicolaus lifted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Finally, Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of "Moderate Buy" and an average price target of $16.00.

Elanco Animal Health Stock Performance

NYSE:ELAN traded up $0.01 during trading hours on Friday, reaching $14.79. The stock had a trading volume of 1,142,084 shares, compared to its average volume of 5,018,695. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.46 and a current ratio of 2.71. The stock has a 50 day simple moving average of $13.82 and a 200 day simple moving average of $11.79. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $15.78. The stock has a market cap of $7.35 billion, a P/E ratio of 19.99, a price-to-earnings-growth ratio of 2.88 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the company posted $0.34 earnings per share. Elanco Animal Health's quarterly revenue was down 1.0% on a year-over-year basis.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC increased its holdings in shares of Elanco Animal Health by 1,153.6% in the fourth quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after buying an additional 37,022,891 shares during the period. Nuveen LLC purchased a new position in shares of Elanco Animal Health in the first quarter worth about $115,212,000. Norges Bank purchased a new position in shares of Elanco Animal Health in the fourth quarter worth about $47,424,000. Dimensional Fund Advisors LP increased its holdings in shares of Elanco Animal Health by 14.3% in the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after buying an additional 2,563,740 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.